Mediwound LTD 20-F annual reports

The annual report filed by foreign private issuers listed on a US exchange — the 10-K’s equivalent for non-US companies.

NASDAQ

5 Mar 2026

MDWD

Mediwound LTD

20-F: MediWound 2025 Annual Report: Losses Persist Amid R&D Push

MediWound Ltd. reported a net loss of $23.9 million for 2025, a decrease from $30.2 million in 2024, as it continues significant investments in R&D and manufacturing expansion for NexoBrid and EscharEx.

NASDAQ

19 Mar 2025

MDWD

Mediwound LTD

20-F: MediWound Reports Full Year 2024 Financial Results and Provides Business Update

MediWound's 2024 20-F filing highlights key financial data, strategic developments, and future outlook for the biopharmaceutical company.

NASDAQ

21 Mar 2024

MDWD

Mediwound LTD

20-F: MediWound's 20-F Filing Reveals Management Changes, Financial Details, and Future Plans

MediWound's 20-F filing highlights management and board changes, financial agreements, and ongoing development of NexoBrid and EscharEx.